: demographic features, clinical presentation and eVects on early neurodevelopment.
Screening for congenital hypothyroidism
The disorder x Congenital hypothyroidism occurs when the newborn's thyroid gland is unable to produce adequate amounts of thyroid hormones. In regions where iodine deficiency is not endemic, the disorder is most often caused by an ectopic or absent thyroid gland. Around 15% have recessively inherited disorders of thyroid hormone biosynthesis. If the infant is not treated, in most cases growth and mental development are seriously compromised. Birth prevalence x About 1:4000 births where iodine deficiency is not endemic. 1 The disorder is about twice as common in girls as in boys.
x Prevalence is lower in Afro-Caribbeans 2 and may be more common in South Asians.
3
Prognosis in the absence of screening x In the absence of early treatment, 40% of aVected individuals have an IQ of less than 70 and 19% of aVected individuals have an IQ of less than 55. The overall mean IQ is about 80. 4 With treatment, much intellectual impairment is avoided, but mean IQ and IQ distribution will not be restored to normal.
5 Even with early diagnosis and treatment, those with severe disease (50% of cases detected by screening) have a mean IQ of about 10 points lower than the general population. There may be increased prevalence of congenital abnormalities and death in infancy. x It is possible that, in some infants, impaired brain development has already occurred that cannot be rectified by postnatal treatment. Screening procedure x Thyroid stimulating hormone (TSH) measurement on filter paper blood spot during first seven days of life on all newborns, followed by thyroxine (T4) measurement on a serum sample when TSH is >20 mU/L; positive rate about 0.3 per 1000 when screened at 4-7 days of life 6 ; 1-3 per 1000 when screened earlier than 4 days. TSH levels in unaffected infants can be high during the first 24 hours because of a neonatal surge, but the surge has usually passed by 2 to 3 days. x Alternatively, T4 measurement followed by TSH measurements when T4 is <10th centile. x Screening could miss rare cases of congenital hypothyroidism -such as hypothalamic pituitary hypothyroidism, compensated disease (normal T4, elevated TSH), or delayed TSH rise; these are very rare (total perhaps 2 or 3 per 100 000). Diagnosis x T4 and TSH measurement in a venous blood sample, obtained as soon as possible after initial positive result. x 90% of those with initial positive results will remain positive. x Detection rate is approximately 90%. The remaining 10% of cases are less severely aVected and do not become detectable by TSH until age 2-6 weeks.
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x Transient hypothyroidism will occur in 10% of infants, 9 or about 2.5 per 100 000 of newborns.
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x Less frequently transient congenital hypothyroidism will occur due to treatment of mothers during pregnancy with thiourea derivatives or iodides Management of infants with positive diagnostic studies x Initially, term newborns are treated with 10-15 mg/kg/day of L_thyroxine.
9 This dose is increased after two weeks if a repeat T4 level is <130 nmol/L. T4 is then maintained between 140 and 200 nmol/L during first year of life,with monthly monitoring.
10 80-90% should have normal TSH by 4 weeks. TSH level is monitored and maintained below 10 mU/L. x Premature newborns are treated until 8 weeks and then monitored to verify that T4 and TSH levels remain normalised. x Infants whose mothers were treated during pregnancy with thiourea derivatives or iodides are monitored to verify that T4 and TSH levels have normalised. Overall assessment x Screening for congenital hypothyroidism in worthwhile. 
